Literature DB >> 15959666

Intravenous immunoglobulin in neurological disorders: a mechanistic perspective.

Namita Misra1, Jagadeesh Bayry, Amal Ephrem, Suryasarathi Dasgupta, Sandrine Delignat, Jean-Paul Duong Van Huyen, Fabienne Prost, Sebastien Lacroix-Desmazes, Antonino Nicoletti, Michel D Kazatchkine, Srini V Kaveri.   

Abstract

Intravenous immunoglobulin (IVIg) has been used in the treatment of primary and secondary antibody deficiencies for over 25 years. It is a safe preparation with no long-term side effects. IVIg was first demonstrated to be effective in autoimmune disorders, two decades ago, in the treatment of acute immune thrombocytopenia. Since then, the therapeutic efficacy of IVIg has been established in Guillain Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis (MG), dermatomyositis (DM), Kawasaki syndrome and the prevention of graft-versus-host disease in recipients of allogeneic bone marrow transplants and reported in a large number of other autoimmune and systemic inflammatory conditions.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15959666     DOI： 10.1007/s00415-005-1102-7

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  51 in total

1.  Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg).

Authors:  T L Vassilev; M D Kazatchkine; J P Duong Van Huyen; M Mekrache; E Bonnin; J C Mani; C Lecroubier; D Korinth; D Baruch; F Schriever; S V Kaveri
Journal:  Blood       Date:  1999-06-01       Impact factor: 22.113

Review 2.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

3.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

Authors:  A Samuelsson; T L Towers; J V Ravetch
Journal:  Science       Date:  2001-01-19       Impact factor: 47.728

4.  Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg).

Authors:  V Hurez; S V Kaveri; A Mouhoub; G Dietrich; J C Mani; D Klatzmann; M D Kazatchkine
Journal:  Ther Immunol       Date:  1994-10

Review 5.  Pooled human IgG modulates cytokine production in lymphocytes and monocytes.

Authors:  U Andersson; L Björk; U Skansén-Saphir; J Andersson
Journal:  Immunol Rev       Date:  1994-06       Impact factor: 12.988

6.  I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome.

Authors:  M K Sharief; D A Ingram; M Swash; E J Thompson
Journal:  Neurology       Date:  1999-06-10       Impact factor: 9.910

7.  Natural antibodies sustain differentiation and maturation of human dendritic cells.

Authors:  Jagadeesh Bayry; Sébastien Lacroix-Desmazes; Vladimira Donkova-Petrini; Cédric Carbonneil; Namita Misra; Yves Lepelletier; Sandrine Delignat; Sooryanarayana Varambally; Eric Oksenhendler; Yves Lévy; Marianne Debré; Michel D Kazatchkine; Olivier Hermine; Srini V Kaveri
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-20       Impact factor: 11.205

8.  Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment.

Authors:  R M Van den Berg-Vos; H Franssen; J H J Wokke; L H Van den Berg
Journal:  Brain       Date:  2002-08       Impact factor: 13.501

9.  Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein.

Authors:  A Pashov; C Dubey; S V Kaveri; B Lectard; Y M Huang; M D Kazatchkine; B Bellon
Journal:  Eur J Immunol       Date:  1998-06       Impact factor: 5.532

10.  Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway.

Authors:  N K Prasad; G Papoff; A Zeuner; E Bonnin; M D Kazatchkine; G Ruberti; S V Kaveri
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422
View more
  5 in total

1.  New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins.

Authors:  Martin Stangel
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

Review 2.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

3.  Development, manufacturing and characterization of a highly purified, liquid immunoglobulin g preparation from human plasma.

Authors:  Inga A Laursen; Lene Blou; John S Sullivan; Peter Bang; Flemming Balstrup; Gunnar Houen
Journal:  Transfus Med Hemother       Date:  2014-04-14       Impact factor: 3.747

Review 4.  Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.

Authors:  Richard Dodel; Frauke Neff; Carmen Noelker; Refik Pul; Yansheng Du; Michael Bacher; Wolfgang Oertel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

Review 5.  Treatment of spinal cord injury with intravenous immunoglobulin G: preliminary evidence and future perspectives.

Authors:  Apostolia Tzekou; Michael G Fehlings
Journal:  J Clin Immunol       Date:  2014-04-11       Impact factor: 8.317
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.